Founded in 1957, it is a well-known trademark in Jilin Province and a pharmaceutical listed company with a series of drugs as its main drug, such as soothing brain fluid / Xuefu Zhuyu oral liquid / brain relixin capsule / heart brain Shutong capsule series
The predecessor of Jilin Aodong Pharmaceutical Group Co., Ltd. was the state-owned Yanbian Dunhua Deer Farm established in 1957, established Aodong Pharmaceutical Factory in 1981, and was restructured into Jilin Aodong Pharmaceutical Group Co., Ltd. in March 1993 with the approval of the Provincial System Reform Commission, and was listed on the Shenzhen Stock Exchange on October 28, 1996.
The company now holds 7 companies engaged in modern traditional Chinese medicine, biochemical drugs and phytochemical drugs, 1 pharmaceutical sales subsidiary, 2 pharmaceutical supporting subsidiaries and shares in GF Securities and Tadong Mining, has planting and breeding bases, and has established an industrial chain business model of "company standardization base and franchised farmers", and has gradually developed into a holding group company integrating pharmaceutical, securities, mining and highway construction industries with "resource sharing, scientific management and sustainable development".
After decades of development, the company has formed a unique brand advantage. The company's leading products "Tranquility and Brain Replenishing Liquid", "Xuefu Zhuyu Oral Liquid", "Brain Heart Capsule", "Heart and Brain Shutong Capsule" have been recognized by the public for many years, "Calf Spleen Extract Injection", "Ribonucleic Acid II for Injection", "Deer Fetal Granules", "Shao Abdominal Zhuyu Granules", "Nourishing Blood Drink Oral Liquid", "Healing Heartache Capsule", "Children's Chai Gui Oral Liquid" and other products have also been well received by the market for their stable quality and exact efficacy, and their sales have increased year by year, laying a solid foundation for the company's sustainable development.
The company will continue to thoroughly implement the policy of "strengthening fine production management, deepening the reform of the marketing system, adjusting the direction of product research and development, promoting the construction of information network, improving the assessment of business objectives, and enhancing the comprehensive strength of the enterprise", create greater value for shareholders, and take into account the interests of consumers, employees, creditors, suppliers and other relevant parties, and contribute to the development of social economy.
